Coronary artery disease (CAD) is one of the most common causes of death worldwide. It is responsible for one-third of deaths in people over 35 years old, with the percentage reaching close to 50% (according to some estimates) in western countries.

The existing treatment is medical, surgical or a combination of both depending on the extent, severity and clinical presentation of CAD & .There has been significant progress made in developing novel strategies for patients suffering from CAD and its associated complications. These strategies have ranged from drugs to robotic surgery to nanotechnology.

Related Articles


Article icon
Pharmacotherapy in Stable CAD: The ISCHEMIA Trial

Published: - Jonathan Yap, Derek P Chew, Gregg W Stone,

Citation: European Cardiology Review 2021;16:e04.

Current Evidence and Future Directions of PCSK9 Inhibition

Published: - Jiaqian Xu, Michael D Shapiro,

Citation: US Cardiology Review 2021;15:e01.

The Core Message of ISCHEMIA

Published: - Kreton Mavromatis, William E Boden,

Citation: European Cardiology Review 2020;15:e64.

ISCHEMIA: A Clinician’s Perspective

Published: - Islam Y Elgendy, Carl J Pepine,

Citation: European Cardiology Review 2020;15:e63.